+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Growth Hormone Market by Application Route of Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4989514
  • Report
  • November 2019
  • Region: Global
  • 212 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AnkeBio Co. Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Ferring BV.
  • Ipsen
  • Merck & Co. Inc.
  • MORE
The global human growth hormone market was valued at $2,840.70 million in 2018 and is expected to reach $5,563.60 million by 2026, registering a CAGR of 8.6% from 2019 to 2026. Human growth hormone is a protein made by the pituitary gland and is secreted into the bloodstream to other parts of the body. Its production is regulated by an intricate set of hormones produced in the hypothalamus gland, intestinal tract, and pancreas. Further, these hormones act on several tissues throughout the body. In adolescents, it stimulates the growth of bone and cartilage. Whereas in adults, it boosts protein production, promotes the utilization of fat, interferes with the action of insulin, and raises blood sugar levels. GH also raises levels of insulin-like growth factor1.

Surge in awareness regarding the effectiveness of growth hormones and increase in prevalence of chronic diseases including growth retardation and pituitary dysfunctions and surge in compliance for growth hormone formulations are the major factors that drive the growth of the global human growth hormone market. However, the side effects associated with its vigorous usage such as muscle pain, joint pain, and fluid retention and high cost of the treatment hampers the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years. Furthermore, rise in disposable income and surge in healthcare expenditure in developing economies is anticipated to create lucrative growth opportunities for the market.

The human growth hormone market can be segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, and small for gestational age, and others . By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. On the basis of distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Application
  • Growth Hormone Deficiency
  • Prader-Willi Syndrome
  • Turner Syndrome
  • Small for Gestational Age
  • Others
By Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Oral
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Pharmacy
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS
  • Novo Nordisk
  • Merck & Co., Inc
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • AnkeBio Co. Ltd
  • F. Hoffmann-La Roche
  • Ipsen
  • Ferring B.V.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnkeBio Co. Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Ferring BV.
  • Ipsen
  • Merck & Co. Inc.
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Research Methodology
1.3.1. Secondary Research
1.3.2. Primary Research
1.3.3. Analyst Tools & Models

Chapter 2: Executive Summary
2.1. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Porter'S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increase In Usage Of Growth Hormone To Control Aging
3.4.1.2. Surge In Disorders Related To Growth Hormone Deficiency
3.4.2. Restraints
3.4.2.1. Side Effects Associated With The Treatment
3.4.3. Opportunities
3.4.3.1. Rise In Awareness Towards Usage Of Human Growth In Developing Economies

Chapter 4: Human Growth Hormone Market, By Application
4.1. Overview
4.1.1. Market Size And Forecast, By Application
4.2. Growth Hormone Deficiency
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Prader-Willi Syndrome
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Turner Syndrome
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Small For Gestational Age (Sga)
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6. Others
4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis, By Country

Chapter 5: Human Growth Hormone Market, By Route Of Administration
5.1. Overview
5.1.1. Market Size And Forecast, By Application
5.2. Oral
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Intravenous
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Intramuscular
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
5.5. Subcutaneous
5.5.1. Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country

Chapter 6: Human Growth Hormone Market, Distribution Channel
6.1. Overview
6.1.1. Market Size And Forecast, Distribution Channel
6.2. Hospital Pharmacy
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country
6.3. Retail Pharmacy
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
6.4. Online Pharmacy
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Analysis, By Country

Chapter 7: Human Growth Hormone Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. Market Size And Forecast, By Application
7.2.3. Market Size And Forecast, By Route Of Administration
7.2.4. Market Size And Forecast, Distribution Channel
7.2.4.1. U.S. Market Size And Forecast, By Application
7.2.4.2. U.S. Market Size And Forecast, By Route Of Administration
7.2.4.3. U.S. Market Size And Forecast, Distribution Channel
7.2.4.4. Canada Market Size And Forecast, By Application
7.2.4.5. Canada Market Size And Forecast, By Route Of Administration
7.2.4.6. Canada Market Size And Forecast, Distribution Channel
7.2.4.7. Mexico Market Size And Forecast, By Application
7.2.4.8. Mexico Market Size And Forecast, By Route Of Administration
7.2.4.9. Mexico Market Size And Forecast, Distribution Channel
7.3. Europe
7.3.1. Key Market Trends And Opportunities
7.3.2. Europe Market Size And Forecast, By Application
7.3.3. Europe Market Size And Forecast, By Route Of Administration
7.3.4. Europe Market Size And Forecast, Distribution Channel
7.3.5. Europe Market Size And Forecast, By Country
7.3.5.1. France Market Size And Forecast, By Application
7.3.5.2. France Market Size And Forecast, By Route Of Administration
7.3.5.3. France Market Size And Forecast, Distribution Channel
7.3.5.4. UK Market Size And Forecast, By Application
7.3.5.5. UK Market Size And Forecast, By Route Of Administration
7.3.5.6. UK Market Size And Forecast, Distribution Channel
7.3.5.7. Germany Market Size And Forecast, By Application
7.3.5.8. Germany Market Size And Forecast, By Route Of Administration
7.3.5.9. Germany Market Size And Forecast, Distribution Channel
7.3.5.10. Spain Market Size And Forecast, By Application
7.3.5.11. Spain Market Size And Forecast, By Route Of Administration
7.3.5.12. Spain Market Size And Forecast, Distribution Channel
7.3.5.13. Rest Of Europe Market Size And Forecast, By Application
7.3.5.14. Rest Of Europe Market Size And Forecast, By Route Of Administration
7.3.5.15. Rest Of Europe Market Size And Forecast, Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends And Opportunities
7.4.2. Asia-Pacific Market Size And Forecast, By Application
7.4.3. Asia-Pacific Market Size And Forecast, By Route Of Administration
7.4.4. Asia-Pacific Market Size And Forecast, Distribution Channel
7.4.5. Asia-Pacific Market Size And Forecast, By Country
7.4.5.1. Japan Market Size And Forecast, By Application
7.4.5.2. Japan Market Size And Forecast, By Route Of Administration
7.4.5.3. Japan Market Size And Forecast, Distribution Channel
7.4.5.4. China Market Size And Forecast, By Application
7.4.5.5. China Market Size And Forecast, By Route Of Administration
7.4.5.6. China Market Size And Forecast, Distribution Channel
7.4.5.7. India Market Size And Forecast, By Application
7.4.5.8. India Market Size And Forecast, By Route Of Administration
7.4.5.9. India Market Size And Forecast, Distribution Channel
7.4.5.10. Australia Market Size And Forecast, By Application
7.4.5.11. Australia Market Size And Forecast, By Application
7.4.5.12. Australia Market Size And Forecast, Distribution Channel
7.4.5.13. Rest Of Asia-Pacific Market Size And Forecast, By Application
7.4.5.14. Rest Of Asia-Pacific Market Size And Forecast, By Route Of Administration
7.4.5.15. Rest Of Asia-Pacific Market Size And Forecast, Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends And Opportunities
7.5.2. LAMEA Market Size And Forecast, By Application
7.5.3. LAMEA Market Size And Forecast, By Route Of Administration
7.5.4. LAMEA Market Size And Forecast, Distribution Channel
7.5.5. LAMEA Market Size And Forecast, By Country
7.5.5.1. Brazil Market Size And Forecast, By Application
7.5.5.2. Brazil Market Size And Forecast, By Route Of Administration
7.5.5.3. Brazil Market Size And Forecast, Distribution Channel
7.5.5.4. Saudi Arabia Market Size And Forecast, By Application
7.5.5.5. Saudi Arabia Market Size And Forecast, By Route Of Administration
7.5.5.6. Saudi Arabia Market Size And Forecast, Distribution Channel
7.5.5.7. South Africa Market Size And Forecast, By Application
7.5.5.8. South Africa Market Size And Forecast, By Route Of Administration
7.5.5.9. South Africa Market Size And Forecast, Distribution Channel
7.5.5.11. Rest Of LAMEA Market Size And Forecast, By Application
7.5.5.12. Rest Of LAMEA Market Size And Forecast, By Route Of Administration
7.5.5.13. Rest Of LAMEA Market Size And Forecast, Distribution Channel

Chapter 8: Company Profiles
8.1. Novo Nordisk
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Merck & Co.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.3. Eli Lilly And Company.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Pfizer Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Teva Pharmaceutical Industries.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Novartis Ag
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Anhui Anke Biotechnology (Group) Co., Ltd.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.8. Roche
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Ipsen
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Ferring Bv
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AnkeBio Co. Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Ferring BV.
  • Ipsen
  • Merck & Co. Inc.
  • MORE
According to the report titled, 'Human Growth Hormone Market by Application, Route of Administration, and Distribution Channel: Global opportunity analysis and industry forecast, 2018-2026', the global human growth hormone market size is expected to reach $5,563 million by 2026, registering a CAGR of 8.6% from 2019 to 2026, in terms of value.

Artificial human growth hormones were developed in 1985 and approved by the FDA for explicit usage in children and adults. In children, growth hormones are approved to treat short height or poor growth due to several medical causes, including Turner syndrome, Prader-Willi syndrome, chronic kidney disease, and hGH deficiency. Whereas, in adults they are used to treat short bowel syndrome, hGH deficiency due to rare pituitary tumors and muscle-wasting disease related to HIV/AIDS. Further, the adoption of human growth hormone to control aging has increased over a period. Significance of human growth hormone in aging is vigorously being explored in clinical and experimental studies. Further, treatment of GH deficient adults with recombinant or artificial human GH (rhGH) improves muscle strength, body composition, physical function, and bone density. In addition, it decreases blood cholesterol and cardiovascular disease risk.

Significant increase in prevalence of chronic diseases including growth retardation, pituitary dysfunctions, and surge in compliance for growth hormone formulations are the major factors that drive the human growth hormone market growth. For instance, incidence of isolated growth hormone deficiency is estimated to be 1 in 4,000 to 10,000 individuals worldwide. Further, growth hormone deficiency occurs in around 1 in 7,000 live births. In addition, increased medical expenditure and disposable incomes in developing nations propels the market growth. However, the side-effects associated with the consumption of these hormones such as muscle pain, joint pain, and fluid retention; and high cost of the treatment hampers the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years.

Based on human growth hormone market analysis, by application, the Turner syndrome segment dominated the market in 2018, and is expected to exhibit a prominent growth rate in the near future, owing to the surge in its incidence across the globe. For instance, according to U.S. National Organization of Rare Disorders, it is estimated that more than 70,000 women and girls in the country have Turner syndrome.

By route of administration, the subcutaneous segment dominated the human growth hormone market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that growth hormones administered subcutaneously have more bioavailability compared to other routes of administration. Currently, most of the artificial growth hormone formulations are being made for subcutaneous route of administration.

Key Finding of The Human Growth Hormone Market:
By application, the Turner Syndrome segment dominated the market in 2018 and is anticipated to continue the same during the forecast period.
By region, North America was the major shareholder and accounted for the highest share of 48% in 2018.
By route of administration, the subcutaneous segment is expected to grow at a CAGR of 9.1% during the forecast period.
By distribution channel, the hospital pharmacy segment dominated the human growth hormone market in 2018 and is anticipated to maintain its dominance during the forecast period.
The human growth hormone market can be segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. On the basis of distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Novo Nordisk, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis AG, AnkeBio Co. Ltd, F. Hoffmann-La Roche, Ipsen, and Ferring BV.
Note: Product cover images may vary from those shown
5 of 5
  • Novo Nordisk
  • Merck & Co. Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • AnkeBio Co. Ltd
  • F. Hoffmann-La Roche
  • Ipsen
  • Ferring BV.
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll